Citation

Menzies EL, Hudson SC, Dargan PI, Parkin MC, Wood DM, Kicman AT. Drug Test. Anal. 2014; 6(6): 506-515.

Affiliation

Drug Control Centre, Analytical and Environmental Sciences Division, School of Biomedical Sciences, King's College London, 150 Stamford Street, London, SE1 9NH, UK.

Copyright

(Copyright © 2014, John Wiley and Sons)

DOI

10.1002/dta.1541

PMID

24574323

Abstract

The classic approach of controlled volunteer studies to study drug metabolism is difficult or impossible to undertake for novel psychoactive substances (NPS), as there is generally very limited information available to allow appropriate dose finding and safety. A viable and powerful alternative is the identification and characterization of phase I and II metabolites of such drugs by examining the concordance of data gathered from analysis of microsomal incubates with that from analysis of specimens collected from individuals with analytically confirmed use of NPS. Liquid chromatography-high resolution mass spectrometry provides the ability to reliably identify such metabolites. We used this technique here to study the metabolism of the ketamine analogue methoxetamine. A large number of metabolites were identified in the in vitro studies including normethoxetamine, O-desmethylmethoxetamine, dihydromethoxetamine, dehydromethoxetamine and several structural isomers of hydroxymethoxetamine and hydroxynormethoxetamine. pH dependent liquid-liquid extraction was used to discriminate phenolic from alcoholic metabolites. Phase II glucuronide conjugates included those of O-desmethylmethoxetamine, O-desmethylnormethoxetamine and O-desmethylhydroxymethoxetamine. The majority of these phase I and II metabolites were confirmed to be present in urine collected from three individuals presenting with acute methoxetamine toxicity. Copyright © 2013 John Wiley & Sons, Ltd.

Language: en